Secondaries announced 12.08.2015
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Kite Pharma, Inc. Symbol: KITE Price: Last trade $74.85 Trade Date: 12/10 Shares: 3.34 million Underwriter(s) Jefferies, Citigroup, Cowen & Co.,[…]